Hofer M, Pospísil M, Znojil V, Holá J, Vacek A, Weiterová L, Streitová D, Kozubík A
Institute of Biophysics, Academy of Sciences of the Czech Republic, Laboratory of Experimental Hamatology, Brno, Czech Republic.
Radiat Res. 2006 Sep;166(3):556-60. doi: 10.1667/RR3598.1.
Meloxicam, a selective inhibitor of cyclooxygenase 2, a nonsteroidal anti-inflammatory drug with an improved side-effects profile in terms of gastrointestinal toxicity, has been found to stimulate hematopoiesis in whole-body gamma-irradiated mice. A distinct corroboration of this positive action of meloxicam is an enhancement of the recovery of hematopoietic progenitor cells committed to granulocyte-macrophage and erythroid development, which has been demonstrated in sublethally irradiated animals treated with meloxicam at a dose of 20 mg/kg administered intraperitoneally either singly 1 h before irradiation or repeatedly after radiation exposure. The results suggest that meloxicam can be added to the list of biological response modifiers that can be used in the treatment of hematopoietic damage induced by ionizing radiation.
美洛昔康是一种环氧化酶2的选择性抑制剂，作为一种非甾体抗炎药，在胃肠道毒性方面具有改善的副作用谱，已被发现在全身γ射线照射的小鼠中能刺激造血。美洛昔康这种积极作用的一个明显确证是，在接受20 mg/kg剂量美洛昔康腹腔注射的亚致死剂量照射动物中，致力于粒细胞-巨噬细胞和红系发育的造血祖细胞的恢复得到增强，美洛昔康在照射前1小时单次给药或在辐射暴露后重复给药。结果表明，美洛昔康可被添加到可用于治疗电离辐射引起的造血损伤的生物反应调节剂名单中。
